Melchior Nierman

Chief Medical Officer

Netherlands

Research Interests

Explore related searches

Professors in Netherlands

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Melchior Nierman serves as the Chief Medical Officer at Atalmedial Medical Diagnostics Centers in the Netherlands. His research primarily focuses on anticoagulation management, with recent publications addressing the safety and effectiveness of switching anticoagulant therapies, particularly in frail older patients and adolescents. He is also involved in studies evaluating the impact of COVID-19 vaccination on anticoagulation stability and the necessity for routine assessments of lipoprotein(a) levels.

Articles (10)

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Collaborators (6)

Sander van Doorn

University Medical Center Groningen

NETHERLANDS

View details

Peter van de Ven

Associate Professor

University Medical Center Utrecht, Utrecht University

NETHERLANDS

View details

Menno Huisman

professor of medicine

Leiden University Medical Center

NETHERLANDS

View details

Nick S Nurmohamed

University of Amsterdam

NETHERLANDS

View details

Suzanne C. Cannegieter

Leiden University Medical Center

NETHERLANDS

View details

Huiberdina L. Koek

University Medical Center Groningen

NETHERLANDS

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Melchior Nierman

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial

The effect of COVID-19 vaccination on anticoagulation stability in adolescents and young adults using vitamin K antagonists

ZorgDomein als oplossing bij inclusieproblemen.

Switching from vitamin K antagonists to direct oral anticoagulants in non‐valvular atrial fibrillation patients: Does low time in therapeutic range affect persistence?

Inter‐ and intra‐individual concentrations of direct oral anticoagulants: The KIDOAC study

Finding very high lipoprotein(a): the need for routine assessment

Working towards personalized anticoagulation management

The Immediate Effect of COVID-19 Vaccination on Anticoagulation Control in Patients Using Vitamin K Antagonists

Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis

Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns

Collaborators (6)

Sander van Doorn

Peter van de Ven

Menno Huisman

Nick S Nurmohamed

Suzanne C. Cannegieter

Huiberdina L. Koek

Make your next move.